Altered elimination of antipyrine in patients with acute viral hepatitis.
Open Access
- 1 May 1976
- Vol. 17 (5) , 341-344
- https://doi.org/10.1136/gut.17.5.341
Abstract
The plasma half-life and clearance of antipyrine was investigated in patients during the acute phase and again during the recovery phase of viral hepatitis. Each patient served as his own control, thereby eliminating genetic factors and minimising environmental factors that cause large interindividual variations in antipyrine elimination rates. Liver function tests, antipyrine, half-life, plasma clearance, and the apparent volume of distribution were determined in the acute and recovery period. It was found that the appaarent volume of distribution of antipyrine did not change in five of six patients as they recovered. Five of the six patients showed prolonged plasma half-lives and decreased plasma clearance of the drug at the time of acute illness and these parameters reached normal values during recovery. The plasma half-life and clearance of the drug did not correlate with biochemical indices of liver function in the recovery phase. This demonstration supports the concept that drug metabolism is frequently impaired in liver disease.Keywords
This publication has 24 references indexed in Scilit:
- Clearance of Antipyrine‐Dependence of Quantitative Liver FunctionEuropean Journal of Clinical Investigation, 1974
- Determinants of serum antipyrine half-lives in patients with liver diseaseGut, 1973
- Relationship between Plasma Antipyrine Half-Lives and Hepatic Microsomal Drug Metabolism in DogsPharmacology, 1973
- MECHANISM OF HEPATIC DRUG OXIDATION AND ITS RELATIONSHIP TO INDIVIDUAL DIFFERENCES IN RATES OF OXIDATION IN MAN*Annals of the New York Academy of Sciences, 1971
- Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in manJournal of Clinical Investigation, 1969
- PHENYLBUTAZONE AND ISONIAZID METABOLISM IN PATIENTS WITH LIVER DISEASE IN RELATION TO PREVIOUS DRUG THERAPYThe Lancet, 1968
- Hepatic Hemodynamics During Viral Hepatitis in ManCirculation, 1966
- RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTIONThe Lancet Healthy Longevity, 1964
- Metabolism of Drugs in Subjects with Laennec’s CirrhosisPharmacology, 1959
- OBSERVATIONS ON THE METABOLIC TRANSFORMATION AND EFFECTS OF PHENYLBUTAZONE IN SUBJECTS WITH HEPATIC DISEASEThe Lancet Healthy Longevity, 1954